Spinal Tech Archives - Page 859 of 1221

10 key facts on the global trauma fixation market

The global trauma fixation market is expected to grow over the next four years, according to a MicroMarket Monitor report.

Zimmer names Michael Farrell to board of directors

Zimmer appointed Michael J. Farrell to its board of directors.

$596M by 2020: Use of composites in orthopedic industry to grow at over 8%

The use of composites in the global orthopedic industry is expected to grow at an average rate of 8.1 percent to reach $596 million by 2020, according to a market report published by ABMRG.

Orthopedic & spine device stock report: 5 key companies — Dec. 30

Here are updates from the past week on five orthopedic and spine device company stock reports.

Building a business around spine customization: Global strategy going forward

Around 20 years ago, Medicrea launched as an orthopedic device company. In 2006, the company went public and began investing in research and development focusing on new technologies to improve standard spinal products.

FDA draft guidance for human cell tissue manipulation — MiMedx responds

The Food and Drug Administration published draft guidance for the minimal manipulation of human cells tissues and cellular and tissue-based products, and now device companies are making comments.

Zyga Technology raises $2M in equity-and-options round

Zyga Technology raised $2 million in an equity-and-options round, hoping to eventually bring in $5 million, according to Mass Device report.

12 key observations on orthopedic device company stock — Zimmer, Medtronic & Stryker

Medtronic, Zimmer or Stryker — who's stock is the best bet?

Stryker is at it again: 5 updates on rumored Smith & Nephew acquisition

More rumors about a potential Stryker acquisition of Smith & Nephew surfaced earlier this week, just as market action slowed for the holidays.

Medtronic executives still get $63M to cover tax inversion — 5 updates on the judge’s decision not to block

Medtronic executives will receive $63 million in payments when the company completes its Covidien acquisition to cover the tax inversion strategy, according to a Star Tribune report.